EP 0057
Alternative Names: EP-0057Latest Information Update: 30 Jun 2023
At a glance
- Originator Ellipses Pharma
- Developer Ellipses Pharma; National Cancer Institute (USA)
- Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Ovarian cancer; Small cell lung cancer
- Phase I/II Prostate cancer; Urogenital cancer
Most Recent Events
- 12 Jun 2023 Ellipses Pharma withdrew a phase II trial due to utility analysis decision to terminate EP 0057 compound in Gastric cancer and Small-cell lung cancer in China, South Korea and Taiwan (NCT05411679)
- 05 May 2023 Ellipses Pharma completes a phase II trial in Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Hungary and United Kingdome (IV) (NCT04669002)
- 09 Jun 2022 Ellipses Pharma plans a phase II trial for Gastric cancer and Small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China, South Korea and Taiwan (IV) in July 2022 (NCT05411679)